There has been a dramatic increase in the use of the GLP‐1 (glucagon‐like peptide‐1) receptor agonists semaglutide and liraglutide, and the GLP‐1/glucose‐dependent insulinotropic polypeptide (GIP) receptor co‐agonist tirzepatide to treat obesity after clinical trials showed that semaglutide and tirzepatide were highly effective for weight reduction and after FDA approval for obesity.1, 2. This evidence concerns the gene GCG and obesity disorder.